Next, using ABE we designed sgRNAs to simultaneously target two genes, Hemoglobin Beta (HBB) and Tumor Protein p53 (TP53), in which mutations cause beta-thalassemia and cancer, respectively20,21 (Fig. 2a). This evidence concerns the gene TP53 and beta thalassemia.